CARsgen Therapeutics Holdings Ltd. (HK:2171) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
CARsgen Therapeutics Holdings Ltd. announced promising results from a pivotal Phase II clinical trial for their CAR T-cell therapy, satricabtagene autoleucel, in treating advanced gastric and gastroesophageal junction cancers. The study demonstrated a statistically significant improvement in progression-free survival, positioning satri-cel as a potential first-in-class treatment. With this advancement, CARsgen continues to enhance its reputation in innovative cancer therapies, focusing on solid tumors.
For further insights into HK:2171 stock, check out TipRanks’ Stock Analysis page.